Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | JAK1 | P23458 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.53 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 5/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | CSK | P41240 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268690 | 0.92 | BTK (0.56) | BTKJAK2JAK3LCKLYN | |
| SCHEMBL15613529 | 0.90 | BTK (0.61) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL15613558 | 0.88 | BTK (0.52) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL18269007 | 0.88 | SRC (0.57) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL18269008 | 0.87 | BTK (0.52) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL18269037 | 0.86 | BTK (0.58) | BTKNUDT14NUDT5LCKSRC | |
| SCHEMBL18269040 | 0.86 | BTK (0.67) | BTKJAK3NUDT14NUDT5LCK | |
| SCHEMBL18268991 | 0.85 | BTK (0.55) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL18269171 | 0.85 | BTK (0.57) | BTKJAK3NUDT14NUDT5LCK | |
| SCHEMBL18269006 | 0.85 | BTK (0.51) | BTKNUDT14NUDT5LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | PHARMASCIENCE INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| WO-2016187723-A1 | INHIBITORS OF THE TEC KINASE ENZYME FAMILY | PHARMASCIENCE INC. (CA) | 2016-12-01 | — | — | WO | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | TEC, BTK, LCK | BTK 2/4885JAK2 311/4885JAK1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.